
    
      The present study was a phase IV, post-marketing, observational study for safety evaluation
      of AlvopemÂ® use in Iranian patients with non-small cell lung cancer and malignant pleural
      mesothelioma.

      Data was gathered in one booklet, which had 6 different periods. The patients' information
      assessed after each injection, every 3 weeks. These booklets were completed by designated
      physicians.

      The primary objective of this study was safety assessment, including the incidence and
      intensity of AEs and SAEs .

      This study was single arm and the sample size of this study was 199 patients.
    
  